About WM-Net
Transforming Research into Clinical Advances for Patients
Our Founding Story
A Network Built for Collaboration
WM-Net was established in 2024 with a simple premise: accelerating progress in Waldenström’s macroglobulinemia requires shared vision, shared data, and shared scientific leadership.
Supported by the International Waldenström’s Macroglobulinemia Foundation (IWMF) and rooted in long-standing collaborative relationships, WM-Net unifies leading clinicians and researchers to address the most important unanswered questions in WM care.
WM-Net is strengthened by the active involvement of the IWMF. The WM-Net leadership team includes Paul Kitchen, Chairman of the IWMF Board, and David Schnell, MD, Trustee and Chair of the Research Strategy Committee. Their participation reflects a shared commitment to aligning scientific and clinical priorities with the needs of the WM community.
Our Mission
Improving Lives Through Scientific Discovery
WM-Net brings together 24 academic medical centers dedicated exclusively to advancing innovative therapies for Waldenström’s macroglobulinemia. Our investigators work collaboratively to design scientifically rigorous clinical trials, accelerate access to new treatments, and translate research into meaningful patient impact.
Every study we lead is guided by one principle: improving outcomes for individuals living with WM today and in the future.
Our 24 Academic Centers
The nation’s foremost WM clinicians and scientists united to accelerate progress.
Behind every WM-Net study is a community of dedicated clinician-scientists driven by a shared vision: improving outcomes for individuals with Waldenström’s macroglobulinemia.
WM-Net’s leadership includes its founding director, Dr. Jorge Castillo (Dana-Farber Cancer Institute), and a national team of investigators representing 24 leading academic medical centers.